By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex said after the close of the market Tuesday that it has renewed its 10-year strategic partnership with One Lambda.

The alliance, which began in 2000, is focused on developing platforms and technologies for human leukocyte antigen typing and antibody screening for the organ transplantation market. One Lamda has developed a range of HLA tests based on Luminex's xMAP technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.